Sanofi (SNY)
(Delayed Data from NSDQ)
$57.63 USD
-0.63 (-1.08%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $57.64 +0.01 (0.02%) 5:22 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Price, Consensus and EPS Surprise
SNY 57.63 -0.63(-1.08%)
Will SNY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SNY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SNY
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
SNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Novavax is Gaining Ground in COVID-19 Vaccine Race
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
Other News for SNY
UnitedHealth, Cigna, CVS PBMs targeted by FTC over inflated insulin prices
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
EU pharma committee takes positive view on AbbVie, Merck, others
Janus Henderson Global Life Sciences Fund Q2 2024 Commentary
Sanofi says tolebrutinib delays symptoms onset for MS by 31%